DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: Airbnb, Oracle, American Express and more
▼ + stars: | 2023-09-05 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Zynex, Coherus BioSciences , Universal Insurance Holdings — Coherus, Zynex and Universal Insurance stock fell on news from S&P 500 Dow Jones indices that the stocks would be moving within small-cap indexes. Coherus is leaving the MidCap 400 for the MidCap 600, while Universal Insurance is leaving the MidCap 600 altogether. American Express — Stock in the credit card giant ticked up 0.5% following an upgrade to outperform from sector perform from RBC earlier Tuesday. The S&P 500 is widely tracked by large index funds, which could create buying pressure on Airbnb's stock in the weeks ahead. Oracle — The software stock added 1.5% in premarket trading following an upgrade to overweight from equal weight by Barclays.

Persons: Dow Jones, Zynex, Airbnb, acquirer Thomas Bravo, —, Alex Harring, Jesse Pound Organizations: New York, Coherus BioSciences, Universal Insurance Holdings, Universal Insurance, RBC, Healthcare, Bloomberg, Oracle, Barclays, Brady, Brady Corporation, FactSet, Warner Bros Locations: Airbnb

Electric vehicle companies Lucid , Fisker and Nikola have had a tough year — and Wall Street expects these stocks have even more downside potential. Nikola, which manufactures electric trucks, has seen its short interest jump nearly 14% to 157.7 million shares, or 27.3% of its float. More than a third of Arcutis Biotherapeutics 's free-float shares have been shorted by Wall Street, or 15.5 million shares. Liver disease treatment company Intercept Pharmaceuticals also saw a 12% jump in short interest, with 9.5 million shares sold short. Below is the full list of the most shorted stocks between July 31 and August 15.

Persons: Nikola, Fisker, Arcutis, scPharmaceuticals, Jerry Durso Organizations: EV, IGM Biosciences, Intercept Pharmaceuticals, U.S . Food, Drug Administration, NASH, Intercept, New York Stock Exchange Locations: FactSet, U.S

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., August 15, 2023. Traders in the U.S. equity options market are bracing for a larger-than-usual swing in Nvidia shares following the chipmaker's earnings, which are due after markets close on Wednesday. ET, Dow e-minis were up 34 points, or 0.1%, S&P 500 e-minis were up 4.25 points, or 0.1%, and Nasdaq 100 e-minis were up 4.75 points, or 0.03%. Peloton Interactive (PTON.O) shares plunged 27% after the fitness equipment maker forecast first-quarter revenue below estimates. Reporting by Amruta Khandekar and Shristi Achar A; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Foot, Susannah Streeter, Hargreaves Lansdown, Jerome Powell, Roche, Armour, Amruta Khandekar, Shinjini Organizations: New York Stock Exchange, REUTERS, Nvidia, Sports, Dow, Nasdaq, Wall, Hargreaves, Traders, Reuters, Federal Reserve, Treasury, Dow e, Biosciences, Merck & Co, Sport, Nike, Thomson Locations: New York City, U.S, Swiss

BERLIN, Aug 23 (Reuters) - Roche (ROG.S) inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The data lifted Roche shares by 5% and sent shares of other companies testing anti-TIGIT drugs higher. J.P. Morgan analysts said the interim data suggested a survival benefit was within reach in the final analysis, but the clinical relevance remained uncertain. The unintended disclosure regards the second interim analysis of a Phase III trial known as Skyscraper 1.

Persons: Roche, tiragolumab, Morgan, Roche's, TIGIT, Paul Arnold, Christy Santhosh, Jason Neely, Friederike Heine, Mark Potter Organizations: Merck & Co, Gilead Sciences, iTeos Therapeutics, Arcus Biosciences, Thomson Locations: U.S, Zurich, Bengaluru

☆ A biotech hedge fund that counts Yale’s endowment among its clients bought a new stake in this genetic testing company
▼ + stars: | 2023-08-16 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing. The biotech stock with a focus on neuroscience has surged more than 84% this year. Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%. The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%. The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.

Persons: Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li Organizations: Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics Locations: InVitae, Invitae, Acadia, ImmunoGen

☆ China’s sitting on a goldmine of genetic data – and it doesn’t want to share
▼ + stars: | 2023-08-11 | by ( Jessie Yeung | ) edition.cnn.com time to read: +14 min

The national survey and restrictions on foreign access are part of new regulations on China’s genetic resources, which came into effect in July. The national genetic surveyBiobanking in China – meaning the collection of biological samples – is still “very fragmented,” and in an “embryonic stage,” said Zhang. But these concerns aren’t new – and the national genetic survey seems to be geared more toward scientific research than other purposes, several experts agreed. But China has another motive, too: establishing what some experts call “genomic sovereignty,” meaning full control of the genetic material within their country. While many other countries also have laws regulating the use and transfer of their population’s genetic material, few are as strict as China’s.

Persons: Guang Niu, ”, Joy Y, Zhang, you’re, Wei Liang, ICHPL, Anna Puglisi, Puglisi, States –, Katherine Wang, ” –, Wang, “, Sun, Xi Jinping, Jiankui, Anthony Wallace, ” Zhang Organizations: Hong Kong CNN, Central South University, Centre for Global Science, biosciences, Shanxi Province Reproductive Science, Communist Party, Georgetown’s Center for Security, Emerging Technology, Gray, Group, CNN, Ministry of Science, Technology, National Health Service, National Institutes of Health, NIH Locations: Hong Kong, China, Changsha, Shanxi Province, Taiyuan, States, “, Wuhan, Xinijang, Xinjiang, Beijing, AFP, Harvard

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and more
▼ + stars: | 2023-08-08 | by ( Brian Evans | ) www.cnbc.com time to read: +4 min

The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. Palantir Technologies — Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Beyond Meat reported an adjusted loss of 83 cents per share on $102.1 million in revenue, while Refinitiv forecasted 86 cents and $108.4 million. Paramount Global — The media conglomerate's shares climbed more than 2% in premarket trading after the company reported a quarterly earnings and revenue beat.

Persons: Goldman Sachs, NASH, Banks, Moody's, Eli Lilly, EchoStar, Charlie Ergen, Refinitiv, Lucid, Palantir, Hims, Simon & Schuster, Yun Li, Samantha Subin, Sarah Min, Pia Singh, Jesse Pound Organizations: Sagimet, Goldman, T Bank, Citizens Financial, Bank of New York Mellon, Truist, JPMorgan Chase, Telsey, Refinitiv, Novo Nordisk —, Dish, United Parcel Service, behemoth, UPS, Palantir, Paramount Global, Paramount, KKR Locations: New York, Banks —

Burps are the top source of methane emissions from cattle. The company this spring began marketing semen with the methane trait in 80 countries. Selecting for the low methane trait could lock in lower and lower emissions for successive generations, she said. Semex is not initially charging extra for the methane trait, said Michael Lohuis, Semex's vice-president of research and innovation. Juha Nousiainen, senior vice-president at Valio, a Finnish dairy, warned that breeding cattle to burp less methane could create digestive problems.

Persons: Nathan Frandino, Loewith's, Loewith, Drew Sloan, Frank Mitloehner, University of California Davis, Mitloehner, Lactanet, Christine Baes, Baes, Michael Lohuis, Burger, Lohuis, Juha Nousiainen, Rod Nickel, Caroline Stauffer, Suzanne Goldenberg Organizations: Johann, REUTERS, University of California, University of Guelph, University of Alberta, biosciences, Canadian, Ottawa, Nestle, Burger King, Restaurant Brands, Thomson Locations: Fresno , California, U.S, WINNIPEG , Manitoba, Lynden , Ontario, Semex, Britain, US, Slovakia, United States, New Zealand, Valio, Winnipeg , Manitoba

☆ Goldman says this little-known biotech stock could more than double
▼ + stars: | 2023-08-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Clinical-stage biopharmaceutical company Sagimet Biosciences could see its treatments reach a breakout stage, which could send its share price soaring, according to Goldman Sachs. The stock has been publicly traded since July 14, and it's trading slightly below its IPO level. Investors are focused on upcoming biopsy results of the second phase of the denifanstat study on liver fat levels, said Tan. Positive results from this phase would support advancement into a pivotal phase three study, she added. The "role of FASN in other indications could offer upside," Tan noted.

Persons: Goldman Sachs, NASH, Andrea Tan, Tan, Denifanstat, FASN, — CNBC's Michael Bloom Organizations: Sagimet Biosciences

☆ Here are Credit Suisse's top picks for August, including healthcare and tech stocks
▼ + stars: | 2023-08-06 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Credit Suisse refreshed its "top of the crop" stock picks for August, betting on some big-name stocks as investors continue to feed the markets with optimism. Credit Suisse recently highlighted several stocks the bank's analysts think can outperform this month. "It is increasingly clear that greater service levels in the form of faster delivery is leading to consumers assigning a higher value to Prime" memberships, Credit Suisse said. Credit Suisse also named electronics manufacturer Flex Ltd. as a top pick. Credit Suisse assigned a $126 price target on Merck, which implies 20% appreciation from Friday's closing price.

Persons: Stocks, Stephen Ju, Amazon's, Ju, Shannon Cross, Flex, Cross, Trung Huynh, Merck, — CNBC's Michael Bloom Organizations: Suisse, Credit Suisse, Amazon, Flex, Merck, Prometheus Biosciences

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. Sales of Gardasil, which prevents cancers caused by HPV, surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. There is room for further Gardasil growth as its use expands into treating males and moves into smaller cities, he added. Despite those challenges, Merck raised its full-year sales forecast to $58.6 to $59.6 billion, from its prior view of $57.7 billion to $58.9 billion.

Persons: Brendan McDermid, Merck, Rob Davis, Davis, Keytruda, Caroline Litchfield, Litchfield, Bill Smead, Prometheus, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, REUTERS, Reuters Connect Companies Merck, Merck & Co, Keytruda, Prometheus Biosciences, Analysts, Prometheus, Smead Capital Management, drugmaker, Thomson Locations: Rahway , New Jersey, U.S, United States, China, Europe, Germany, New York, Bengaluru

☆ Merck beats quarterly sales estimate on top drugs' strength
▼ + stars: | 2023-08-01 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Companies Merck & Co Inc FollowAug 1 (Reuters) - Merck & Co (MRK.N) posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. Sales of Gardasil, which prevents cancers caused by HPV, surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. Merck said it now expects full-year sales of $58.6 to $59.6 billion, up from its prior view of $57.7 billion to $58.9 billion.

Persons: Merck, Rob Davis, Davis, Keytruda, Cantor Fitzgerald, Louise Chen, Prometheus, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, Merck & Co, Merck's, Prometheus Biosciences, Analysts, Prometheus, Thomson Locations: United States, China, U.S, New York, Bengaluru

☆ Merck CEO Rob Davis on Q2 results: We continue to see phenomenal growth
▼ + stars: | 2023-08-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMerck CEO Rob Davis on Q2 results: We continue to see phenomenal growthMerck chairman and CEO Rob Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil, but posted a quarterly loss due to its acquisition of the biotech company Prometheus Biosciences earlier this year.

Persons: Rob Davis Organizations: Merck, Prometheus Biosciences

☆ Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
▼ + stars: | 2023-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company's acquisition of Prometheus Biosciences earlier this year. Merck swung to a net loss of $5.98 billion, or $2.35 per share, from a net income of $3.94 billion, or $1.55 per share, during the year-earlier period. The loss reflects a $10.2 billion, or $4.02 per share, charge related to the company's acquisition of Prometheus, which specializes in treatments for autoimmune diseases. "What you really see...was long sustained underlying growth, and it was driven by oncology and vaccines, and the Gardasil franchise in vaccines," Merck CEO Robert Davis said in an interview on CNBC's "Squawk Box" on Tuesday.

Persons: Merck, Robert Davis Organizations: Merck, Prometheus Biosciences, Prometheus, Refinitiv Locations: U.S

☆ Earnings playbook: How to trade some of the biggest reports this week, including Apple
▼ + stars: | 2023-07-31 | by ( Fred Imbert | ) www.cnbc.com time to read: +8 min

This quarter: Analysts polled by FactSet expect Merck to post a loss for the first quarter. Starbucks is set to report earnings after the bell, with management slated to hold a call at 5 p.m. This quarter: Analysts polled by FactSet expect double-digit earnings growth quarter over quarter. What history shows: Bespoke data shows Amazon earnings exceed earnings expectations 62% of the time. Apple is set to report earnings after the close, followed by a call at 5 p.m.

Persons: Goldman Sachs, Annika Kim Constantino, Merck, Merck's, Joe Biden's, SBUX, Bank of America's Sara Senatore, Senatore, Albert Bourla, —, They're, AMZN, FactSet, Annie Palmer, Morgan Stanley, Erik Woodring, — CNBC's Michael Bloom Organizations: Netflix, Merck, Apple, FactSet, CNBC, Prometheus Biosciences, Investment, Bank of America's, Pfizer, Management, Amazon Web Services, IDC Locations: China, 2Q23, New York, Carolina, Friday's

☆ On tap this week: Jobs report plus 10 key earnings. Here's what we want to see
▼ + stars: | 2023-07-29 | by ( Zev Fima | ) www.cnbc.com time to read: +18 min

All three major averages advanced for the week, powered by strong mega-cap earnings and favorable inflation data. Looking to next week, earnings season enters its second half with the last of our mega-caps — Apple (AAPL) and Amazon (AMZN) — set to report on Thursday. We'll get a better read on the employment picture on Wednesday with the ADP report and then, more importantly, on Friday's nonfarm payrolls report for July. Thursday after the close brings us to the main events of the week: Earnings from Apple and Amazon. For those looking to review first quarter performance ahead of these releases, be sure to keep our first-quarter earnings report card handy.

Persons: We'll, that's, Stanley Black, Decker, Emerson, Bausch, Leggett, Platt, SIRI, Ares, COLM, PERI, Kraft Heinz, Phillips, Ferrari N.V, Johnson, Robinson, COOK, BUD, Kellogg, Papa, Pitney Bowes, Parker, Trimble, Ziff Davis, Nonfarm, Jim Cramer's, Jim Cramer, Jim, Apple Tim Cook, Kevin Dietsch Organizations: Nasdaq, Dow, Federal Reserve, Federal, ISM Manufacturing, Services PMI, Investors, Caterpillar, Devices, Starbucks, Natural Resources, AMD, Management, Emerson Electric and, Humana, Bausch Health, Apple, Microsoft, Resource Partners, AerCap Holdings, CNA Financial Corp, CNA, Apellis Pharmaceuticals, Bank, SJW, Hutchison China MediTech, Camtek Ltd, Silvercrest Asset Management, Loews Corp, Oxford Lane Capital Corp, Banco Santander, Silicom Ltd, SuperCom Ltd, Arista Networks, Avis Budget Group, Diamondback Energy, Lattice Semiconductor Corp, Republic Services, Yum China Holdings, Western Digital Corp, Power Systems, Tenet Healthcare Corp, Vornado Realty, BioMarin Pharmaceutical, PetMed, SBA Communications Corporation, Brixmor, Snack Foods Corp, Cushman & Wakefield, Sanmina Corporation, TFI, PMI, Cruise Line Holdings Ltd, Uber Technologies, Pfizer, Enterprise Products Partners, Merck, JetBlue Airways Corporation, Allegro MicroSystems, Altria, SunPower Corp, SiriusXM Holdings, Molson Coors Beverage, Marriott International, Toyota Motor Corp, BP, SYSCO Corp, Marathon Petroleum Corp, Ares Management, Equitrans Midstream Corporation, Game Technology, Illinois Tool, IDEXX Laboratories, Rockwell Automation, Packaging International Corp, Gartner, Zebra Technologies Corp, IQVIA Holdings, Oshkosh Corporation, Leidos Holdings, Eaton Corp, yte Corp, Lear Corp, Starbucks Corp, Devon Energy Corp, SolarEdge Technologies, Lumen Technologies, Virgin Galactic Holdings, Caesars Entertainment, VF Corp, Sciences Corp, Paycom, Vertex Pharmaceuticals, Suncor Energy, Holdings, Chesapeake Energy Corp, Boston Properties, American International Group, AIG, Allstate Corp, Aspen Technology, Electronic Arts, EA, Flowserve Corporation, Denny's, Corp, Prudential Financial, Store, Ternium S.A, Vimeo, Emerson, Lomb, CVS Health, Generac Holdings, Cameco Corp, Perion Network Ltd, Builders, Carlyle Group, Scorpio, Teva Pharmaceutical Industries, Ltd, Rithm Capital Corp, AeroSystems Holdings, Vertiv Holdings Co, Johnson Controls, CDW Corp, DuPont, Brands Holdings, Scotts Miracle, Gro, SMG, Brands, Allegheny Technologies, AmerisourceBergen Corporation, ABC, Real Estate Corporation, Adient plc, Editas, Garmin Ltd, WWE, Bunge Ltd, Criteo S.A, PayPal, QUALCOMM, Occidental Petroleum Corp, Apache Corp, Albemarle Corp, MGM Resorts International, MGM, Marathon Oil Corp, Joby Aviation, Industrial, CF Industries Holdings, Goodyear Tire &, Realty ome Corp, Metlife, Pacific Biosciences of, Rush Street Interactive, Zillow, JFrog Ltd, Herbalife Nutrition Ltd, Simon Property Group, McKesson Corp, Storage, Cerus Corporation, GXO Logistics, MAX Holdings, Health, Anheuser, Busch InBev, Warner Bros ., Cheniere Energy, ConocoPhillips, Hasbro, CIGNA Corp, Lantheus Holdings, Regeneron Pharmaceuticals, Fiverr International, Air Products & Chemicals, TopBuild Corp, EPAM Systems, Lightspeed Commerce, Aurinia Pharmaceuticals, Cummins, CMI, Slair Corporation, Starwood Property Trust, Vulcan, Alnylam Pharmaceuticals, New Energy Corp, Cedar Fair Entertainment, Intellia Therapeutics, Lending, Privia Health, Dickinson, Chimera Investment, CIM, Hyatt Hotels Corp, Lion Electric, LEV, Deluxe Corp, Murphy Oil Corp, PBF Energy, Papa John's, Targa Resources Corp, Wix.com Ltd, Apollo Global Management, LLC, Butterfly, Sempra Energy, Aptiv PLC, Brookfield Infrastructure Partners, Canada Goose Holdings, Hannifin Corporation, WESCO International, WCC, Arrow Electronics, Constellation Energy Group, Midstream Partners, Coinbase, Petroleo Brasileiro SA Petrobras, Gilead Sciences, Opendoor Technologies, Booking Holdings, Atlassian Corporation, International, Redfin Corporation, Motorola Solutions, Monster Beverage Corporation, Consolidated Edison, Rocket Companies, Apple Hospitality, Cirrus, Resources, Universal Display Corporation, Chesapeake Utilities Corp, Social, Defense, Security Solutions, Post Holdings, Tandem Diabetes Care, Nikola Corporation, Magna International, Dominion Energy, ACM Research, Frontier Communications, Brookfield Renewable Partners, inTEST Corporation, American Pipeline, TELUS International, XPO Logistics, Fluor Corp, Gray Television, Cboe, LyondellBasell Industries, Twist Bioscience, Global, Jim Cramer's Charitable, CNBC, Allen & Company Sun Valley, Getty Locations: U.S, China, India, Oxford, Chile, Illinois, Columbia, Pacific, Pacific Biosciences of California, Southern, PBI, Gilead, Sun Valley , Idaho

NEW YORK, July 25 (Reuters) - Joe Lewis, the British billionaire and owner of the Tottenham Hotspur soccer team, has been criminally charged in New York for orchestrating a "brazen" insider trading scheme. Joe Lewis is a wealthy man," U.S. Attorney Damian Williams said in a video on the X social media platform, formerly known as Twitter. Insider trading has long been a focus of Williams' office, dating to 2009 when a crackdown began under one of his predecessors, Preet Bharara. Prosecutors said that in some insider trading cases, Lewis lent money to recipients of his tips, including in Oct. 2019 when he wired $1 million to two pilots so they could buy more Mirati shares. Reporting by Jonathan Stempel and Luc Cohen in New York; Editing by Chris Reese and Lincoln Feast.

Persons: Joe Lewis, Lewis, Damian Williams, " Williams, Williams, Preet Bharara, Mirati, Boss, Marty, JPMorgan Chase, Jonathan Stempel, Luc Cohen, Chris Reese, Lincoln Organizations: YORK, Tottenham Hotspur, Prosecutors, U.S, Tavistock Group, Forbes, Therapeutics, Biosciences, Australian Agricultural, U.S . Securities, Exchange Commission, JPMorgan, Thomson Locations: New York, Tavistock, Bear Stearns

☆ Billionaire Joe Lewis has been charged with insider trading, with prosecutors saying he helped personal pilots, assistants, and romantic partners make 'millions'
▼ + stars: | 2023-07-26 | by ( Grace Dean | ) www.businessinsider.com time to read: +5 min

Tottenham Hotspur owner Joe Lewis has been charged by federal prosecutors with insider trading. The British billionaire passed information to his pilots, assistants, and romantic partners, an indictment says. In one case cited, Lewis is said to have lent his pilots $500,000 each to buy stock before insider information became public. British billionaire Joe Lewis has been charged by federal prosecutors with insider trading, with prosecutors saying that he passed information to personal pilots, assistants, romantic partners, and a friend he played poker with. According to the indictment, Lewis even gave his pilots $500,000 each in short-term loans so that they could buy stock before the news became public.

Persons: Joe Lewis, Lewis, Damian Williams, Williams, David M, Zornow, Mr, Mirati, couldn't Organizations: Tottenham Hotspur, Morning, Court, Southern, of, US, Bloomberg, Tavistock Group, English, Solid Biosciences, Australian Agricultural Company Locations: of New York, Bahamas, Argentina, Queensland, Tavistock, Mirati

☆ Using AI to monitor orphaned elephants in Botswana could usher in the return of the woolly mammoth
▼ + stars: | 2023-07-19 | by ( Tom Page | ) edition.cnn.com time to read: +7 min

The startup has entered a collaboration with Elephant Havens, a wildlife foundation based in the Okavango Delta that cares for orphaned elephants. The findings, the organizations hope, could provide a blueprint for releasing the elephants into the wild and mammoth hybrids to the tundra. A new system for elephant monitoringHuman-wildlife conflict is the leading cause of elephant orphans in Botswana, says Elephant Havens founder Debra Stevens. After five years in the enclosure, Elephant Havens will reintroduce these bonded herds into the wild, and monitor their progress for a decade. Biotech company Colossal wants to create a hybrid combining mammoth DNA with that of Asian elephants.

Persons: “, –, Elephant, We’ll, ”, Matt James, Debra Stevens, “ That’s, Stevens, revel, Havens, Steve Metzler, Dr, Wendy Kiso, James, Debra, ” James, Ben Lamm, ” Lamm, Lamm Organizations: CNN, Colossal Biosciences, Biotech company Colossal, Colossal Locations: Botswana, Africa, rewilding, America

☆ Lightning Round: I like Stellantis even though people think it's too cheap, says Jim Cramer
▼ + stars: | 2023-07-19 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: I like Stellantis even though people think it's too cheap, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stocks including: Tripadvisor, Luminar, Shockwave Medical, Stellantis, Akoya Biosciences, Vitesse Energy, Pfizer, and Vistra.

Persons: Jim Cramer Organizations: Shockwave, Akoya Biosciences, Vitesse Energy, Pfizer

☆ Cramer's Lightning Round: Trip advisor isn't good enough
▼ + stars: | 2023-07-19 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Tripadvisor's year-to-date stock performance. Stock Chart Icon Stock chart icon Shockwave Medical's year-to-date stock performance. Stock Chart Icon Stock chart icon Akoya Biosciences' year-to-date stock performance. Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon Vistra's year-to-date stock perforrmance.

Persons: Brian Chesky, Shockwave, Stellantis, it's, you've, Bourla, he's, George Organizations: Technologies, Luminar Technologies, Biosciences, Akoya Biosciences, Vitesse Energy's, Vitesse Energy, Pfizer

☆ Exclusive: MoonLake Immunotherapeutics explores sale-sources
▼ + stars: | 2023-07-14 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

July 14 (Reuters) - MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter. Immunology-focused companies have been coveted acquisition targets, as highlighted by recent deals such as Merck & Co's (MRK.N) $10.8 billion acquisition of Prometheus BioSciences Inc and Eli Lilly's (LLY.N) $2.4 billion purchase of Dice Therapeutics (DICE.O). MoonLake is testing Sonelokimab for the treatment of other inflammatory conditions, including psoriatic arthritis and psoriasis. If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG (NOVN.S) and AbbVie Inc (ABBV.N). In 2022, MoonLake went public through a merger with a special purpose acquisition company, which helped it raise more than $200 million in cash.

Persons: drugmakers, Eli Lilly's, MoonLake, hidradenitis suppurativa, hidradenitis, Merck KGaA, David Carnevali, Josie Kao Organizations: Nasdaq, Merck, Co's, Prometheus BioSciences, Dice Therapeutics, Novartis AG, AbbVie Inc, Citigroup, Thomson Locations: Zug, Switzerland, New York

☆ Cramer's Lightning Round: Palantir is a buy
▼ + stars: | 2023-07-10 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Rambus's year-to-date stock performance. Stock Chart Icon Stock chart icon Palantir's year-to-date stock performance. Stock Chart Icon Stock chart icon Coherus Biosciences's year-to-date stock performanceCoherus Biosciences : "I've got to tell you, it's a very hard drug to make... Look, it's a good spec, let's just leave it at that." Stock Chart Icon Stock chart icon Commercial Metals's year-to-date stock performance. I like the metal recycling business, and I think it's terrific, second only to Nucor, as far as I'm concerned in that group."

Persons: Coherus, I've Organizations: Metals

☆ Pfizer makes equity investment in Caribou Biosciences
▼ + stars: | 2023-07-06 | by ( ) www.reuters.com time to read: +2 min

July 6 (Reuters) - Pfizer (PFE.N) has invested $25 million to buy a minority stake in Caribou Biosciences (CRBU.O), making it the latest small biotechnology firm to attract the pharmaceutical giant's interest. The news lifted shares of Caribou more than 61% in early trade. Pfizer purchased nearly 4.7 million Caribou shares at $5.33 per share, Caribou said on Thursday, representing a premium of about 30% over Caribou's previous close price. This represents 7.64% of outstanding shares in Caribou, according to Reuters' calculation based on Refinitiv IBES data. It also made a $25 million equity investment in Akero Therapeutics (AKRO.O) last year.

Persons: Caribou, NASH, Jennifer Doudna, Raghav Mahobe, Leroy Leo, Maju Samuel Organizations: Pfizer, Caribou Biosciences, Biohaven Pharmaceutical, Akero Therapeutics, Thomson Locations: Caribou, California, Bengaluru

Search resuls for: "BioSciences"

25 mentions found